Intuit Regulatory Limited logo

Latest News

Read the latest developments and projects for the Intuit Team

PharmAust canine phase 2b cancer trial expands to New Zealand.

15 November 2021 – Perth, Australia

PharmAust Limited (ASX: PAA & PAAO), a clinical-stage biotechnology company, has signed agreements with Veterinary Specialists Auckland and Intuit Regulatory to expand its canine Phase 2b lymphoma studies into New Zealand, in preparation for its Phase 3 trial anticipated to commence in May 2022. 

PharmAust has signed an agreement with Dr Mike Coleman DVM and Dr Tommy Fluen DVM, both fellows of the Australian and New Zealand College of Veterinary Scientists and both registered specialists in small animal internal medicine. They both work at Veterinary Specialists Auckland and can accept dog lymphoma referrals in New Zealand’s North Island. 

Dr Tommy Fluen stated, “We look forward to working with PharmAust and trial Principal Investigator Dr Kim Agnew to test the hypothesis that monepantel will provide a well-tolerated oral therapy for canines with lymphoma, which is superior to steroids alone and without the costs and risks of chemotherapy.” 

Principal Investigator Dr Kim Agnew stated, “It is always very beneficial for any product development building towards a Phase 3 study to expand knowledge in new market settings so having the NZ team combine with our team is very good for the PharmAust program.” 
PharmAust’s Chief Scientific Officer Dr Richard Mollard stated, “PharmAust is delighted to work with Dr Coleman, Dr Fluen and Dr McNab to establish a clinical trial site in New Zealand. Establishing trial procedures, structures and systems with these groups and receiving their feedback will provide great value to PharmAust in preparing for Phase 3 and potentially later with product roll-out.”